A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy.
A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy. Breast Cancer Res Treat. 2026 Sep 22; 219(3).
PMID: 42773273
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
PMID: 42530945
Breast cancer recurrence and mortality among survivors of childhood cancer.
Breast cancer recurrence and mortality among survivors of childhood cancer. J Natl Cancer Inst. 2026 Sep 01; 118(9):1753-1757.
PMID: 41499441
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy. medRxiv. 2026 Jul 29.
PMID: 42619946
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence. medRxiv. 2026 May 12.
PMID: 42180367
Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach.
Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520666.
PMID: 42030501
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
PMID: 42018670
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer.
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520834.
PMID: 41990285
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression. Breast Cancer (Dove Med Press). 2026; 18:569936.
PMID: 42006742
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520506.
PMID: 41962061